Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18.
As the leader in HIV innovation, Gilead will provide an update on its strategic initiatives, key collaborations, and share new scientific data from its HIV research and development programs. The research that will be presented at EACS 2025, along with the Gilead-led symposia and supported community forums, reflect the company’s person-centered approach to advancing scientific discovery and underscores its focus on community partnership to help end the HIV epidemic.
HIV Prevention Research
Reaching underserved populations with PrEP: The Phase 2 PURPOSE 5 trial in France and the UK successfully recruited people not previously engaged in HIV prevention, using community collaboration and targeted strategies. It evaluates the use of twice-yearly lenacapavir for PrEP.
Safety of lenacapavir with other medications: Data from the PURPOSE 2 trial show that lenacapavir can be safely used with statins and PDE-5 inhibitors (e.g., for cholesterol and erectile dysfunction), with appropriate monitoring due to its effect on the CYP3A4 enzyme.
HIV Treatment Research
Five-year real-world data from BICSTaR: Long-term results from Canada, France, and Germany confirm that Biktarvy maintains viral suppression, has a good safety profile, and is effective even in people with multiple co-morbidities. Patient-reported outcomes highlight its positive impact on quality of life and mental health.
ARTISTRY-1 demographic insights: Baseline data from this Phase 3 study show the need for simpler treatment options. It evaluates switching from complex regimens to a once-daily oral combination of bictegravir and lenacapavir. Final results are expected by year-end.
Islatravir + Lenacapavir (weekly oral): At 96 weeks, this investigational once-weekly regimen maintained viral suppression in nearly all participants, showing promise as the first weekly oral HIV treatment. Two Phase 3 trials (ISLEND-1 and ISLEND-2) are ongoing.
Lenacapavir + bNAbs (twice-yearly): A Phase 2 study showed that combining lenacapavir with broadly neutralizing antibodies (bNAbs) maintained viral suppression for 52 weeks. This could become the first complete HIV treatment given just twice a year and is moving into Phase 3 trials.